You are here

Home » Content

Investigating the frequency of 460C / T VEGF gene in prostate cancer patients in North West of Iran

Journal Name:

  • Cumhuriyet Üniversitesi Fen Fakültesi Fen Bilimleri Dergisi

Publication Year:

  • 2015

Key Words:

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Vascular endothelial growth factor (VEGF) is an important angiogenic factor and its role in tumor progression has been identified. Several polymorphisms of VEGF have been identified. Due to the potential role variants, VEGF460 C / T in prostate cancer, we hypothesized that these variants associated with prostate cancer risk. For this purpose, a normal control group of 50 healthy subjects and 50 patients with prostate cancer were studied. Polymorphisms of VEGF 460 C / T with the BSTUI restriction enzyme analyzed based on polymerase chain reaction. In this research, analyzes of variants VEGF460 C / T in term of T polymorphism revealed a significant difference.
Bookmark/Search this post with
FULL TEXT (PDF): 
PDF icon 5000120565-5000204690-1-pb.pdf
  • 4
156
163
  • English

REFERENCES

References: 

[1] Dirican A, Erten C, Atmaca H, Bozkurt E, Kucukzeybek Y, Varol U, et al. Enhanced cytotoxicity and apoptosis by thymoquinone in combination with zoledronic acid in hormone- and drug-resistant prostate cancer cell lines. Journal of BUON: official journal of the Balkan Union of Oncology. 2014;19[4]:1055-61.
[2] Tverdal A. Boiled coffee consumption and the risk of prostate cancer: follow-up of 224,234 Norwegian men 20-69 years. British journal of cancer. 2014.
[3] Thakur V, Talwar M, Singh PP. Low free to total PSA ratio is not a good discriminator of chronic prostatitis and prostate cancer: An Indian experience. Indian journal of cancer. 2014;51[3]:335-7.
[4] Nasu Y. [Gene therapy for castration resistant prostate cancer]. Nihon rinsho Japanese journal of clinical medicine. 2014;72[12]:2152-7.
[5] Chen Z, Lan X, Thomas-Ahner JM, Wu D, Liu X, Ye Z, et al. Agonist and antagonist switch DNA motifs recognized by human androgen receptor in prostate cancer. The EMBO journal. 2014.
[6] Zhu Y, Wang HK, Qu YY, Ye DW. Prostate cancer in East Asia: evolving trend over the last decade. Asian journal of andrology. 2014.
[7] Discacciati A, Wolk A. Lifestyle and dietary factors in prostate cancer prevention. Recent results in cancer research Fortschritte der Krebsforschung Progres dans les recherches sur le cancer. 2014;202:27-37.
[8] Zare-Mirzaie A, Balvayeh P, Imamhadi MA, Lotfi M. The frequency of latent prostate carcinoma in autopsies of over 50 years old males, the Iranian experience. Medical journal of the Islamic Republic of Iran. 2012;26[2]:73-7.
[9] Liu JB, Dai CM, Su XY, Cao L, Qin R, Kong QB. Gene Microarray Assessment of Multiple Genes and Signal Pathways Involved in Androgen-dependent Prostate Cancer Becoming Androgen Independent. Asian Pacific journal of cancer prevention : APJCP. 2014;15[22]:9791-5.
[10] Gilbert R, Bonilla C, Metcalfe C, Lewis S, Evans DM, Fraser WD, et al. Associations of vitamin D pathway genes with circulating 25-hydroxyvitamin-D, 1,25-dihydroxyvitamin-D, and prostate cancer: a nested case-control study. Cancer causes & control : CCC. 2014.
[11] Gu L, Frommel SC, Oakes CC, Simon R, Grupp K, Gerig CY, et al. BAZ2A [TIP5] is involved in epigenetic alterations in prostate cancer and its overexpression predicts disease recurrence. Nature genetics. 2014.
[12] von Wahlde MK, Hulsewig C, Ruckert C, Gotte M, Kiesel L, Bernemann C. The anti-androgen drug dutasteride renders triple negative breast cancer cells more sensitive to chemotherapy via inhibition of HIF-1alpha-/VEGF-signaling. Gynecological endocrinology: the official journal of the International Society of Gynecological Endocrinology. 2014:1-5.
[13] Kuroyanagi J, Shimada Y, Zhang B, Ariyoshi M, Umemoto N, Nishimura Y, et al. Zinc finger MYND-type containing 8 promotes tumour angiogenesis via induction of vascular endothelial growth factor-A expression. FEBS letters. 2014;588[18]:3409-16.
[14] Ngollo M, Lebert A, Dagdemir A, Judes G, Karsli-Ceppioglu S, Daures M, et al. The association between Histone 3 Lysine 27 Trimethylation [H3K27me3] and prostate cancer: relationship with clinicopathological parameters. BMC cancer. 2014;14[1]:994.
[15] Di Sante G, Pestell TG, Casimiro MC, Bisetto S, Powell MJ, Lisanti MP, et al. Loss of sirt1 promotes prostatic intraepithelial neoplasia, reduces mitophagy, and delays park2 translocation to mitochondria. The American journal of pathology. 2015;185[1]:266-79.
[16] Sfar S, Hassen E, Saad H, Mosbah F, Chouchane L. Association of VEGF genetic polymorphisms with prostate carcinoma risk and clinical outcome. Cytokine. 2006;35[1-2]:21-8.
MEHNİ, FARAJNİA, FAKHRJOU
163
[17] Lin C-C, Wu H-C, Tsai F-J, Chen H-Y, Chen W-C. Vascular endothelial growth factor gene− 460 C/T polymorphism is a biomarker for prostate cancer. Urology. 2003;62[2]:374-7.
[18] Langsenlehner T, Langsenlehner U, Renner W, Krippl P, Mayer R, Wascher TC, et al. Single nucleotide polymorphisms and haplotypes in the gene for vascular endothelial growth factor and risk of prostate cancer. European Journal of Cancer. 2008;44[11]:1572-6.
[19] Chuang CH, Liu CH, Lu TJ, Hu ML. Suppression of alpha-tocopherol ether-linked acetic acid in VEGF-induced angiogenesis and the possible mechanisms in human umbilical vein endothelial cells. Toxicology and applied pharmacology. 2014;281[3]:310-6.
[20] Jackson MW, Bentel JM, Tilley WD. Vascular endothelial growth factor [VEGF] expression in prostate cancer and benign prostatic hyperplasia. The Journal of urology. 1997;157[6]:2323-8.
[21] Ferrer FA, Miller LJ, Andrawis RI, Kurtzman SH, Albertsen PC, Laudone VP, et al. Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells. Urology. 1998;51[1]:161-7.
[22] Mandic A, Usaj Knezevic S, Kapicl Ivkovic T. Tissue expression of VEGF in cervical intraepithelial neoplasia and cervical cancer. Journal of BUON : official journal of the Balkan Union of Oncology. 2014;19[4]:958-64.
[23] Jones A, Fujiyama C, Turner K, Fuggle S, Cranston D, Bicknell R, et al. Elevated serum vascular endothelial growth factor in patients with hormone‐escaped prostate cancer. BJU international. 2000;85[3]:276-80.
[24] STEWART RJ, PANIGRAHY D, FLYNN E, FOLKMAN J. VASCULAR ENDOTHELIAL GROWTH FACTOR EXPRESSION AND TUMOR ANGIOGENESIS ARE REGULATED BY ANDROGENS IN HORMONE RESPONSIVE HUMAN PROSTATE CARCINOMA:: EVIDENCE FOR ANDROGEN DEPENDENT DESTABILIZATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR TRANSCRIPTS. The Journal of urology. 2001;165[2]:688-93.
[25] Ferrer FA, Miller LJ, Lindquist R, Kowalczyk P, Laudone VP, Albertsen PC, et al. Expression of vascular endothelial growth factor receptors in human prostate cancer. Urology. 1999;54[3]:567-72.
[26] Haxho F, Allison S, Alghamdi F, Brodhagen L, Kuta VE, Abdulkhalek S, et al. Oseltamivir phosphate monotherapy ablates tumor neovascularization, growth, and metastasis in mouse model of human triple-negative breast adenocarcinoma. Breast Cancer [Dove Med Press]. 2014;6:191-203.
[27] Asano E, Ebara T, Yamada-Namikawa C, Kitaori T, Suzumori N, Katano K, et al. Genotyping Analysis for the 46 C/T Polymorphism of Coagulation Factor XII and the Involvement of Factor XII Activity in Patients with Recurrent Pregnancy Loss. PloS one. 2014;9[12]:e114452

Thank you for copying data from http://www.arastirmax.com